Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Dr Reddy

Dr Reddy's Laboratories launches generic Sugammadex injection in the United States

Dr Reddy's Laboratories has launched its generic Sugammadex injection in the United States. This new product reverses muscle relaxant effects given during surgical procedures. The company's hospital portfolio expands with this important medicine's availability. Sugammadex injection is a vertically integrated product manufactured through Dr Reddy's global network. This launch occurred…

The Economic Times

Dr Reddy’s shares crack 9% after weak Q1; these 3 brokerages slash their target prices

Dr Reddy’s shares plunged 9% on Thursday after the drugmaker reported a weak Q1 FY27 performance, with net profit tumbling 69% year-on-year to Rs 443 crore and revenue declining 6% to Rs 8,071 crore. Earnings were hit by a Rs 240 crore semaglutide API-related impact, including inventory provisions, while higher…

The Economic Times

Stocks in news: Infosys, IndusInd Bank, Eternal, Adani Green, Dr Reddy's

Indian markets experienced a decline on Wednesday due to global and geopolitical concerns. IndusInd Bank reported a significant profit increase while Eternal saw substantial net profit growth. BPCL, however, posted a considerable loss in the first quarter. Adani Green announced a moderate profit rise, and Dr Reddy's profit declined. Several…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks in news: DMart, HCL Tech, ICICI Pru AMC, Dr Reddy’s, NTPC, IndiGo

Markets saw a strong rebound on Friday, driven by global cues and IT earnings. HCL Tech and ICICI Pru AMC will announce their first quarter results today. DMart reported an 11.3% rise in net profit, while Tata Motors launched a new edition. Dr Reddy's faces supply issues, and IndiGo received…

The Economic Times

Dr Reddy's shares crash 9% in 2 days; brokerages slash target prices after semaglutide supply disruption. What lies ahead?

Dr Reddy's Laboratories shares extended their decline after the company delayed commercial supplies of its semaglutide product due to a quality-related API issue. While brokerages remain broadly positive on the long-term outlook, several have cut target prices and earnings estimates, citing near-term execution risks and slower product ramp-up.

The Economic Times

Dr Reddy's shares slide 7% after delay in semaglutide supplies over quality concerns

Dr Reddy's shares fell sharply on Thursday after the company delayed commercial supplies of its semaglutide product due to a quality issue involving the active pharmaceutical ingredient (API). The company said patient safety and regulatory filings remain unaffected, while an investigation is underway to identify the root cause and restore…

The Economic Times

Dr Reddy's flags quality issue in semaglutide batches, delays commercial supplies

Dr Reddy's Laboratories has announced a setback in the distribution of their semaglutide products attributed to out-of-specification batches associated with an active ingredient concern. The firm is actively investigating to identify the source of the problem and is implementing corrective strategies.

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

Stocks in news: Dr Reddy’s, Adani Green, KIMS, JSW Energy, Nestle India

Markets saw a strong rebound on Friday, driven by positive global cues and easing geopolitical tensions. Nifty defended the 23,000 support and reclaimed 23,500, with potential for further gains. Several stocks like Dr Reddy's, Adani Green, and JSW Energy are in focus due to significant corporate developments.

The Economic Times

Dr Reddy's launches oral semaglutide biosimilar Obeda in India

Dr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This innovative treatment offers patients the ease of a once-daily oral dosage, available in various strengths to effectively enhance glycaemic control. Dr.

The Economic Times

Stocks in news: Vodafone Idea, Indian Oil, Tata Steel, Dr Reddy's, PFC

Markets closed lower amid geopolitical tensions, rupee weakness, and rising inflation. Upcoming week will be sensitive to US-Iran conflict implications for oil and inflation. Vodafone Idea reported a Rs 51,970 crore net profit due to an accounting gain, while Tata Steel and Hindustan Copper saw significant profit growth in Q4FY26.

The Economic Times

Dr Reddy’s launches generic Semaglutide injection, popular weight-loss drug, in Canada

Dr Reddy's Laboratories has launched its generic Semaglutide injection in Canada. This marks a significant step for the company in providing treatment for type 2 diabetes. Canada is the first G7 nation to approve this medication. The launch follows a recent introduction in India. Dr Reddy's aims to expand access…

The Economic Times

Dr. Reddy's Laboratories Q4 Earnings Call Highlights

Dr. Reddy's Laboratories (NYSE:RDY) reported what Chief Financial Officer M.V. Narasimham described as a resilient FY 2026 performance, with record annual revenue despite pressure from lower lenalidomide sales and several one-time charges during the fourth quarter. Narasimham said the company’s und

MarketBeat

Dr Reddy's shares in focus after Q4 net profit tumbles 86% YoY; Morgan Stanley, Goldman Sachs weigh in

Dr. Reddy's Laboratories shares: The pharma major posted a sharp 86% YoY drop in Q4FY26 consolidated net profit to Rs 221 crore, compared with Rs 1,587 crore a year ago. Following the weak earnings performance, several brokerages cut their target prices on the stock.

The Economic Times

Stocks in news: Airtel, Tata Motors, Dr Reddy's, NTPC, Dixon Technologies

Markets faced selling pressure on Tuesday due to weak global cues and macroeconomic concerns, with the Nifty approaching support at 23,150. Several companies like Airtel, Tata Motors, and Dr Reddy's are in focus due to earnings reports and other news developments.

The Economic Times

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Stocks in news: Groww, Dr Reddy's, Waaree Energies, Lenskart, SBI

Markets experienced a sharp risk-off session on Monday, with indices declining amid broad selling. Investors are advised to avoid aggressive index bets and await clearer directional signals. Pharma and healthcare stocks remain preferred, while dips in energy and metal sectors offer accumulation opportunities.

International Business Times

Dr. Reddy's Strategic Vision Reiterated Following Strong Q1FY25 Results

Dr. Reddy's reported consolidated revenues of ₹7,673 crores (US$ 921 million) for Q1FY25, marking a 14% year-on-year increase and a 8% sequential growth.

People

Reddy

30 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.